ChemPartner Makes Additional Investments in Biologics from Research to Manufacturing Capabilities
Shanghai, China (June 9, 2020) – Shanghai ChemPartner announced the additional investments the company is
making into its biologics business unit to further its capabilities and capacity in biologics discovery through development
“ChemPartner has rich experience in providing biologics discovery and development services,” said Wei Tang, CEO
at ChemPartner. “Our exceptional scientists on our biologics discovery and development teams provide one-stop
services for overall process development and IND application, and the expansion of our biologics cGMP manufacturing
capacity shows we are aligned and dedicated to technically and strategically accomplishing the research initiatives of
pharmaceutical and biotech companies worldwide.”
ChemPartner has opened its newest facility, which is located in Qidong, China outside of Shanghai. This 67,000 m2
campus includes a laboratory center with 5,000 m2 animal facility, administration building, and biologics production
plant. The biologics production plant will start operation in August 2020.
The 13,000 m2 Phase I biologics production plant complies with the highest standards and guidelines set by the ICH,
FDA, NMPA, and EMPA and aims to fulfill the biologics production demands for clients globally during clinical phase
III and commercial launch. This facility will accommodate up to eight 2,000 L and three 500 L single-use bioreactors
as well as one 2-20 mL vial aseptic filling and freeze-drying line. ChemPartner also has well-equipped analytical
facilities to support method development and product release testing.
Dr. Jun Xiang, General Manager of ChemPartner Biologics added, “Investment in this state-of-the-art biologics
manufacturing facility is a major milestone for ChemPartner. This newest addition makes ChemPartner a truly world
class CDMO that will continue to help our global clients bring their biologic therapeutics to the market.”
ChemPartner’s biologics discovery team’s experience and capabilities to discover and characterize therapeutic
antibodies and fusion proteins are rapidly growing, led by western-trained PhDs and supported by ChemPartner’s
biology and pharmacology and DMPK and exploratory toxicology departments. Services include B cell cloning, targetspecific
functional assays, antibody engineering, developability and in silico assessment and protein sciences.
ChemPartner is working on projects at various clinical stages. With the expansion in services, personnel, and facilities,
the seamless transition from biologics discovery to biologics development and manufacturing offers tailored services
for ChemPartner’s clients. The biologics CMC development and cGMP manufacturing team consists of senior
scientists, engineers, and leaders with extensive experiences in process development and cGMP manufacturing.
Shanghai ChemPartner, which includes ChemPartner, ChemPartner Biologics, and China Gateway Pharmaceutical
Development, offers a broad range of drug discovery, development, and manufacturing services including chemistry
and biologics discovery, biology and pharmacology, DMPK and exploratory toxicology, and small molecule and
biologics CMC development and manufacturing. Shanghai ChemPartner serves a diverse global client base and has
laboratories, business offices, and representatives in the US, Europe, China, and Japan.
FOR MORE INFORMATION
Livia Legg, MS, Chief Commercial Officer